What's in a color? GSK wins injunction against Sandoz
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has won the first round in a battle with Novartis's generics arm Sandoz over the color purple. A German court has handed down a preliminary injunction blocking Sandoz from selling its salmeterol/fluticasone product, AirFluSal Forspiro. The injunction is related to the fact that the colors of the AirFluSal Forspiro inhaler and GSK's Advair (salmeterol/fluticasone) are similar.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.